丙型肝炎直接抗病毒治疗与肝癌发生及复发的关系  

Association of direct-acting antiviral therapy for hepatitis C with the development and recurrence of liver cancer

作　　者：李砚 刘蕾[2] 罗书兰[3] 罗超 汤善宏[3] 

机构地区：[1]中国人民解放军第四十二医院感染科,四川乐山614000 [2]成都市第三人民医院医学实验部,成都610000 [3]成都军区总医院消化科,成都610000

出　　处：《临床肝胆病杂志》2018年第2期410-413,共4页Journal of Clinical Hepatology

摘　　要：HCV感染后引起的慢性肝炎,是导致肝硬化和肝细胞癌的主要原因之一。近年来,直接抗病毒药物(DAA)逐渐成为治疗丙型肝炎的主流药物。研究表明DAA可能会增加HCV相关肝硬化患者发生肝癌或者导致肝癌复发的风险,给DAA的临床应用带来了巨大的争议。综述了DAA对肝癌发生和复发的影响,以期为DAA的临床应用提供更好的依据。Chronic hepatitis caused by hepatitis C virus（HCV） infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma.In recent years,direct-acting antiviral agents（DAAs） have gradually become main drugs for the treatment of hepatitis C.Studies have shown that DAAs may increase the risk of the development or recurrence of liver cancer in patients with HCV-related liver cirrhosis,which causes great controversies over the clinical application of DAAs.This article reviews the influence of DAAs on the development and recurrence of liver cancer,in order to provide a better basis for the clinical application of DAAs.

关 键 词：肝炎 丙型 癌 肝细胞 抗病毒药 综述 

分 类 号：R521.63[医药卫生—内科学] R735.7[医药卫生—临床医学]